Aurora Acquires Safari Flower: A Strategic Expansion Into Global Medical Cannabis

In a move that underscores where the cannabis industry is truly heading, Aurora Cannabis Inc. has announced the acquisition of Safari Flower Company for approximately $26.5 million. On the surface, it’s a straightforward acquisition. But when you look closer, it becomes clear this is a highly intentional step toward deepening Aurora’s dominance in international medical cannabis markets, particularly those demanding pharmaceutical-grade quality.

This is not about chasing scale for the sake of it. It’s about precision expansion into high-margin, tightly regulated global markets, and doing so with infrastructure that’s already built to meet those standards.

A Closer Look at the Aurora and Safari Deal

Aurora’s acquisition of Safari Flower Company was executed through a wholly owned subsidiary, securing 100% ownership of the business. The total consideration of $26.5 million includes a mix of cash and equity, reflecting a balanced approach to growth and capital management.

At closing, Aurora paid $15 million in cash and issued 2,417,180 common shares to the seller. An additional $2 million cash payment remains contingent on certain conditions being met post-closing. This structure allows Aurora to align incentives while maintaining flexibility as it integrates the new asset into its broader operations.

The transaction itself is expected to generate positive Adjusted EBITDA by fiscal 2027, with further financial upside anticipated into 2028 as efficiencies are realized and production is optimized.

The Real Asset: EU GMP-Certified Infrastructure

What makes Safari Flower Company such a valuable acquisition is not just its production capacity; it’s their compliance. The company operates a 59,000-square-foot, purpose-built indoor cultivation and manufacturing facility in Ontario, and critically, it is EU GMP certified. That certification signals that the facility meets the strict pharmaceutical manufacturing standards required to export cannabis into highly regulated international medical markets.

For Aurora, this is a major strategic advantage.

Rather than building new infrastructure from the ground up, a process that can take years of regulatory approvals and capital investment, Aurora is acquiring ready-to-deploy, export-qualified capacity. This immediately strengthens its ability to supply key international markets such as Germany, Australia, Poland, and the United Kingdom, all of which require strict adherence to EU GMP standards.

Why This Matters: The Rise of Global Medical Cannabis

Aurora’s CEO and Executive Chairman Miguel Martin described the acquisition as a “milestone,” emphasizing the company’s intent to expand its EU GMP capacity to support the rapidly growing international medical cannabis market.

That statement reflects a larger industry reality that the future of cannabis, at least from a profitability standpoint, is increasingly tied to medical markets outside North America. Unlike the often-volatile recreational markets, international medical cannabis markets tend to offer:

• More consistent demand driven by patient needs

• Stronger pricing power for high-quality products

• Regulatory frameworks that prioritize safety and consistency

Aurora is leaning directly into this opportunity. By increasing its supply of EU GMP-manufactured cannabis flower, the company is positioning itself to capture greater market share in regions where quality is non-negotiable and margins are significantly higher.

Leveraging Science and Scale

Another key theme in their press release is Aurora’s focus on plant science and operational expertise. This is not just marketing language; it’s central to how the company plans to extract value from the acquisition.

Aurora has built its reputation on data-driven cultivation practices, and it intends to apply that expertise to Safari’s operations to improve cultivation yields, enhance consistency in product quality, and increase overall production efficiency. The goal is not simply to maintain Safari’s output, but to elevate it, turning an already compliant facility into a more productive and cost-efficient component of Aurora’s global supply chain.

This also supports Aurora’s broader strategy of optimizing its network of cultivation and manufacturing sites, ensuring that each facility plays a specific role in serving targeted markets.

Strengthening the Global Supply Chain

One of the most important takeaways from this acquisition is how it enhances Aurora’s end-to-end supply chain. With additional EU GMP-certified capacity, Aurora can:

• Better align production with international demand

• Reduce bottlenecks in export-ready supply

• Ensure consistent delivery to key medical markets

This kind of supply chain control is critical in a global industry where delays, inconsistencies, or regulatory missteps can quickly erode trust with both patients and partners. By integrating Safari into its existing infrastructure, Aurora is effectively building a more resilient and scalable global distribution system.

Financial Outlook and Long-Term Value

Aurora has made it clear that this acquisition is expected to be accretive, contributing positively to its financial performance over time. While the benefits will not be immediate, the company anticipates positive adjusted EBITDA contributions starting in fiscal year 2027. They also expect increasing financial returns in fiscal 2028 and beyond as operations are optimized.

This measured timeline reflects the realities of scaling in a regulated industry. It takes time to integrate facilities, align operations, and expand into new markets, but once established, those channels tend to deliver stable, recurring revenue.

A Strategic Shift Toward High-Margin Markets

Perhaps the most telling aspect of this acquisition is what it says about Aurora’s priorities moving forward.

The company is clearly focused on:

• High-margin international markets rather than saturated domestic ones

• Medical cannabis over recreational volume

• Quality and compliance over rapid expansion

This marks a continued evolution in Aurora’s strategy from early industry growth fueled by scale to a more refined approach centered on profitability and sustainability.

Navigating Risks in a Complex Industry

As with any acquisition, Aurora acknowledges there are risks. The company highlighted factors such as integration challenges, regulatory changes, market competition, and operational execution as potential variables that could impact outcomes. There are also broader considerations, including global trade dynamics and the ability to maintain consistent product quality across expanding operations.

However, these risks are inherent to operating in a global, highly regulated sector and Aurora’s emphasis on compliance and operational discipline suggests it is well aware of the challenges ahead.

Final Thoughts: Building for What Comes Next

Aurora’s acquisition of Safari Flower Company is not about short-term headlines; it’s about long-term positioning. By investing in EU GMP-certified infrastructure, expanding its international supply capabilities, and focusing on high-margin medical markets, the company is laying the groundwork for sustained global growth.

The cannabis industry is maturing, and with that maturity comes a shift in what defines success. It’s no longer just about how much you can produce, but about where you can sell it, how consistently you can deliver it, and whether you can meet the highest standards in the world. With this acquisition, Aurora is making it clear: it intends to compete and lead on all three fronts.